430 related articles for article (PubMed ID: 33634707)
21. Prostate Specific Antigen and Prostate Specific Antigen Doubling Time Predict Findings on
Markowski MC; Sedhom R; Fu W; Gray JCR; Eisenberger MA; Pomper MG; Pienta KJ; Gorin MA; Rowe SP
J Urol; 2020 Sep; 204(3):496-502. PubMed ID: 32250727
[TBL] [Abstract][Full Text] [Related]
22. Pelvic lymph-node staging with
Jansen BHE; Bodar YJL; Zwezerijnen GJC; Meijer D; van der Voorn JP; Nieuwenhuijzen JA; Wondergem M; Roeleveld TA; Boellaard R; Hoekstra OS; van Moorselaar RJA; Oprea-Lager DE; Vis AN
Eur J Nucl Med Mol Imaging; 2021 Feb; 48(2):509-520. PubMed ID: 32789599
[TBL] [Abstract][Full Text] [Related]
23. Impact of
Basso Dias A; Finelli A; Bauman G; Veit-Haibach P; Berlin A; Ortega C; Avery L; Metser U
Radiology; 2022 Sep; 304(3):600-608. PubMed ID: 35608445
[TBL] [Abstract][Full Text] [Related]
24. Early lesion detection with
Wondergem M; Jansen BHE; van der Zant FM; van der Sluis TM; Knol RJJ; van Kalmthout LWM; Hoekstra OS; van Moorselaar RJA; Oprea-Lager DE; Vis AN
Eur J Nucl Med Mol Imaging; 2019 Aug; 46(9):1911-1918. PubMed ID: 31230088
[TBL] [Abstract][Full Text] [Related]
25. [
Alemozaffar M; Akintayo AA; Abiodun-Ojo OA; Patil D; Saeed F; Huang Y; Osunkoya AO; Goodman MM; Sanda M; Schuster DM
J Urol; 2020 Oct; 204(4):734-740. PubMed ID: 32347780
[TBL] [Abstract][Full Text] [Related]
26. Prospective Validation of Gallium-68 Prostate Specific Membrane Antigen-Positron Emission Tomography/Computerized Tomography for Primary Staging of Prostate Cancer.
van Kalmthout LWM; van Melick HHE; Lavalaye J; Meijer RP; Kooistra A; de Klerk JMH; Braat AJAT; Kaldeway HP; de Bruin PC; de Keizer B; Lam MGEH
J Urol; 2020 Mar; 203(3):537-545. PubMed ID: 31487220
[TBL] [Abstract][Full Text] [Related]
27.
Wondergem M; van der Zant FM; Knol RJJ; Lazarenko SV; Pruim J; de Jong IJ
J Nucl Med; 2017 Nov; 58(11):1797-1804. PubMed ID: 28450569
[TBL] [Abstract][Full Text] [Related]
28. Role of
Zhang T; Yang S; Lin L; Wang S; Xia D; Chen D; Wang G; Zhao K; Su X
Hell J Nucl Med; 2022; 25(1):11-18. PubMed ID: 35388799
[TBL] [Abstract][Full Text] [Related]
29. Multisite Experience of the Safety, Detection Rate and Diagnostic Performance of Fluciclovine (
Bach-Gansmo T; Nanni C; Nieh PT; Zanoni L; Bogsrud TV; Sletten H; Korsan KA; Kieboom J; Tade FI; Odewole O; Chau A; Ward P; Goodman MM; Fanti S; Schuster DM; Willoch F
J Urol; 2017 Mar; 197(3 Pt 1):676-683. PubMed ID: 27746282
[TBL] [Abstract][Full Text] [Related]
30. Intraindividual Comparison of
Giesel FL; Will L; Lawal I; Lengana T; Kratochwil C; Vorster M; Neels O; Reyneke F; Haberkon U; Kopka K; Sathekge M
J Nucl Med; 2018 Jul; 59(7):1076-1080. PubMed ID: 29269569
[TBL] [Abstract][Full Text] [Related]
31. Repeatability of Quantitative
Jansen BHE; Cysouw MCF; Vis AN; van Moorselaar RJA; Voortman J; Bodar YJL; Schober PR; Hendrikse NH; Hoekstra OS; Boellaard R; Oprea-Lager DE
J Nucl Med; 2020 Sep; 61(9):1320-1325. PubMed ID: 31924729
[TBL] [Abstract][Full Text] [Related]
32. Predictors of
Mena E; Rowe SP; Shih JH; Lindenberg L; Turkbey B; Fourquet A; Lin FI; Adler S; Eclarinal P; McKinney YL; Citrin DE; Dahut W; Wood BJ; Chang R; Levy E; Merino M; Gorin MA; Pomper MG; Pinto PA; Eary JF; Choyke PL; Pienta KJ
J Nucl Med; 2022 Aug; 63(8):1184-1190. PubMed ID: 34916246
[TBL] [Abstract][Full Text] [Related]
33. Diagnostic Performance and Safety of
Jani AB; Ravizzini GC; Gartrell BA; Siegel BA; Twardowski P; Saltzstein D; Fleming MT; Chau A; Davis P; Chapin BF; Schuster DM;
J Urol; 2023 Aug; 210(2):299-311. PubMed ID: 37126069
[TBL] [Abstract][Full Text] [Related]
34. [
Perry E; Talwar A; Taubman K; Ng M; Wong LM; Booth R; Sutherland TR
Eur J Nucl Med Mol Imaging; 2021 Jun; 48(6):2038-2046. PubMed ID: 33399941
[TBL] [Abstract][Full Text] [Related]
35. Lesion Detection and Interobserver Agreement with Advanced Image Reconstruction for
Jansen BHE; Jansen RW; Wondergem M; Srbljin S; de Klerk JMH; Lissenberg-Witte BI; Vis AN; van Moorselaar RJA; Boellaard R; Hoekstra OS; Oprea-Lager DE
J Nucl Med; 2020 Feb; 61(2):210-216. PubMed ID: 31481580
[TBL] [Abstract][Full Text] [Related]
36. Outcomes of Primary Lymph Node Staging of Intermediate and High Risk Prostate Cancer with
Yaxley JW; Raveenthiran S; Nouhaud FX; Samartunga H; Yaxley AJ; Coughlin G; Delahunt B; Egevad L; McEwan L; Wong D
J Urol; 2019 Apr; 201(4):815-820. PubMed ID: 30672842
[TBL] [Abstract][Full Text] [Related]
37. Metastasized 18F-DCFPyL-Negative Prostatic Adenocarcinoma Without Neuroendocrine Differentiation.
Broos WAM; Kocken M; van der Zant FM; Knol RJJ; Wondergem M
Clin Nucl Med; 2018 Feb; 43(2):120-122. PubMed ID: 29261618
[TBL] [Abstract][Full Text] [Related]
38. Patterns of disease detection using [
Koschel S; Taubman K; Sutherland T; Yap K; Chao M; Guerrieri M; Benson A; Starmans M; Byrne G; Ong G; Macleod C; Foo M; Wong LM; Gyomber D; Ng M
Eur J Nucl Med Mol Imaging; 2021 Oct; 48(11):3712-3722. PubMed ID: 33852051
[TBL] [Abstract][Full Text] [Related]
39. Comparison of [(18)F]DCFPyL and [ (68)Ga]Ga-PSMA-HBED-CC for PSMA-PET Imaging in Patients with Relapsed Prostate Cancer.
Dietlein M; Kobe C; Kuhnert G; Stockter S; Fischer T; Schomäcker K; Schmidt M; Dietlein F; Zlatopolskiy BD; Krapf P; Richarz R; Neubauer S; Drzezga A; Neumaier B
Mol Imaging Biol; 2015 Aug; 17(4):575-84. PubMed ID: 26013479
[TBL] [Abstract][Full Text] [Related]
40. Imaging of metastatic clear cell renal cell carcinoma with PSMA-targeted ¹⁸F-DCFPyL PET/CT.
Rowe SP; Gorin MA; Hammers HJ; Som Javadi M; Hawasli H; Szabo Z; Cho SY; Pomper MG; Allaf ME
Ann Nucl Med; 2015 Dec; 29(10):877-82. PubMed ID: 26286635
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
